🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Kabir Mody

ORCID: 0000-0003-3254-2990

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma”.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.02.005

N/A

0.868DataRank · unranked

326 citations

S.L. Chan, R.K. Kelley, G. Lau, M. Kudo, W. Sukeepaisarnjaroen +198 more

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma

JAMA Oncology(2020)10.1001/jamaoncol.2020.4930

N/A

0.795DataRank · unranked

200 citations

Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Daniel Almquist, Syeda A. Mina, Jehad Almasri +13 more

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study

European Journal of Cancer(2021)10.1016/j.ejca.2021.03.028

N/A

0.604DataRank · unranked

55 citations

Tanios Bekaii‐Saab, Patrick M. Boland, Farshid Dayyani, Teresa Macarulla, Kabir Mody +8 more

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.12.011

N/A

0.538DataRank · unranked

35 citations

Daniel DiToro, Francesco Facchinetti, E Martin, P. Peng, Islam Baiev +50 more

Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)

Investigational New Drugs(2021)10.1007/s10637-021-01090-w

N/A

0.360DataRank · unranked

10 citations

Nathan R. Foster, Amit Mahipal, Thomas Byrne, Joleen M. Hubbard, Alvin Silva +4 more

Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy

Journal of Vascular and Interventional Radiology(2024)10.1016/j.jvir.2024.11.012

N/A

0DataRank · unranked

10 citations

Suryansh Bajaj, Aiwu He, Kabir Mody, Ryan Hickey, Ammar Sarwar +4 more

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad046

N/A

0DataRank · unranked

28 citations

Leontios Pappas, Islam Baiev, Jordan R. Maurer, Andrea Grace Bocobo, Karen Zhang +25 more

Cell-Free Tumor DNA Dominant Clone Allele Frequency (DCAF) Is Associated With Poor Outcomes In Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy

medRxiv(2021)10.1101/2021.11.01.21265773

N/A

0DataRank · unranked

0 citations

Umair Majeed, Jun Yin, Gehan Botrus, Mohamad Bassam Sonbol, Daniel H. Ahn +25 more

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.150

N/A

0DataRank · unranked

143 citations

Francesco Facchinetti, Daniel DiToro, Islam Baiev, Umair Majeed, Sylvia A. Reyes +24 more